Literature DB >> 30847806

Treatment of Vulvodynia: Pharmacological and Non-Pharmacological Approaches.

Natalie O Rosen1,2,3, Samantha J Dawson4, Melissa Brooks5, Susan Kellogg-Spadt6,7.   

Abstract

Vulvodynia is a common, recurrent, vulvar pain condition with debilitating consequences for affected women's health and quality of life. The heterogeneity of women suffering from vulvodynia as well as its uncertain and likely multifactorial etiology pose a significant challenge to identifying any kind of "gold standard" treatment. Thus, treatment providers must be well versed in the various options and the evidence for each. In this review, we begin with pharmacological treatments, followed by non-pharmacological treatments, surgery, and finally multimodal treatments. For each approach, we briefly discuss the method, mechanism of action, and empirical support for the treatment. In sum, pharmacological treatments that may be beneficial but require further research include antinociceptive agents (lidocaine, capsaicin), anti-inflammatory agents (corticosteroids, interferon), neuromodulating medications (anticonvulsants and antidepressants), hormonal agents, and muscle relaxants (e.g., botulinum toxin). There is strong evidence to support and recommend non-pharmacological interventions including psychological therapy, pelvic floor physical therapy, as well as surgery (i.e., vestibulectomy for provoked vestibulodynia) for the treatment of vulvodynia. We conclude this review with a discussion of issues that may have hindered progress of treatment efficacy and effectiveness, and recommendations for moving the field forward.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30847806     DOI: 10.1007/s40265-019-01085-1

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  130 in total

1.  Gabapentin therapy for vulvodynia.

Authors:  B Ben-David; M Friedman
Journal:  Anesth Analg       Date:  1999-12       Impact factor: 5.108

2.  Acupuncture for the treatment of vulvar vestibulitis: a pilot study.

Authors:  I Danielsson; I Sjöberg; C Ostman
Journal:  Acta Obstet Gynecol Scand       Date:  2001-05       Impact factor: 3.636

3.  Capsaicin and nociception: from basic mechanisms to novel drugs.

Authors:  R Baron
Journal:  Lancet       Date:  2000-09-02       Impact factor: 79.321

4.  A randomized comparison of group cognitive--behavioral therapy, surface electromyographic biofeedback, and vestibulectomy in the treatment of dyspareunia resulting from vulvar vestibulitis.

Authors:  Sophie Bergeron; Yitzchak M Binik; Samir Khalifé; Kelly Pagidas; Howard I Glazer; Marta Meana; Rhonda Amsel
Journal:  Pain       Date:  2001-04       Impact factor: 6.961

5.  Treating vulvar vestibulitis with electromyographic biofeedback of pelvic floor musculature.

Authors:  E McKay; R H Kaufman; U Doctor; Z Berkova; H Glazer; V Redko
Journal:  J Reprod Med       Date:  2001-04       Impact factor: 0.142

6.  Acupuncture for vulvodynia.

Authors:  J Powell; F Wojnarowska
Journal:  J R Soc Med       Date:  1999-11       Impact factor: 5.344

7.  Cromolyn cream for recalcitrant idiopathic vulvar vestibulitis: results of a placebo controlled study.

Authors:  P Nyirjesy; J D Sobel; M V Weitz; D J Leaman; M J Small; S P Gelone
Journal:  Sex Transm Infect       Date:  2001-02       Impact factor: 3.519

8.  Vulvar vestibulitis syndrome: an often unrecognized cause of dyspareunia.

Authors:  R Pagano
Journal:  Aust N Z J Obstet Gynaecol       Date:  1999-02       Impact factor: 2.100

9.  Prevalence and predictors of chronic lower genital tract discomfort.

Authors:  B L Harlow; L A Wise; E G Stewart
Journal:  Am J Obstet Gynecol       Date:  2001-09       Impact factor: 8.661

10.  Treatment of vulvar vestibulitis with submucous infiltrations of methylprednisolone and lidocaine. An alternative approach.

Authors:  F Murina; P Tassan; P Roberti; V Bianco
Journal:  J Reprod Med       Date:  2001-08       Impact factor: 0.142

View more
  7 in total

Review 1.  Approach to Diagnosis and Management of Chronic Pelvic Pain in Women: Incorporating Chronic Overlapping Pain Conditions in Assessment and Management.

Authors:  Sara R Till; Reina Nakamura; Andrew Schrepf; Sawsan As-Sanie
Journal:  Obstet Gynecol Clin North Am       Date:  2022-06       Impact factor: 2.838

Review 2.  Vulvodynia.

Authors:  Sophie Bergeron; Barbara D Reed; Ursula Wesselmann; Nina Bohm-Starke
Journal:  Nat Rev Dis Primers       Date:  2020-04-30       Impact factor: 52.329

3.  Internet-based treatment for vulvodynia (EMBLA) - Study protocol for a randomised controlled study.

Authors:  Andrea Hess Hess Engström; Merit Kullinger; Izabella Jawad; Susanne Hesselman; Monica Buhrman; Ulf Högberg; Alkistis Skalkidou
Journal:  Internet Interv       Date:  2021-04-20

4.  Evaluation of Gut Microbiota in Patients With Vulvovestibular Syndrome.

Authors:  Laura Coda; Paola Cassis; Stefania Angioletti; Cristina Angeloni; Stefania Piloni; Cristian Testa
Journal:  J Clin Med Res       Date:  2021-02-25

5.  Online Information on Painful Sexual Dysfunction in Women: Quality Analysis of Websites in SPANISH about Dyspareunia, Vaginismus and Vulvodynia.

Authors:  Andrea Vicente-Neira; Virginia Prieto-Gómez; Beatriz Navarro-Brazález; Cristina Lirio-Romero; Javier Bailón-Cerezo; María Torres-Lacomba
Journal:  Int J Environ Res Public Health       Date:  2022-01-28       Impact factor: 3.390

6.  Is It Possible to Improve Urinary Incontinence and Quality of Life in Female Patients? A Clinical Evaluation of the Efficacy of Top Flat Magnetic Stimulation Technology.

Authors:  Graziella Lopopolo; Benedetta Salsi; Alessandra Banfi; Pablo González Isaza; Irene Fusco
Journal:  Bioengineering (Basel)       Date:  2022-03-25

Review 7.  Female Sexual Dysfunctions and Urogynecological Complaints: A Narrative Review.

Authors:  Lavinia Mosca; Gaetano Riemma; Andrea Braga; Matteo Frigerio; Alessandro Ferdinando Ruffolo; Mattia Dominoni; Gaetano Maria Munno; Stefano Uccella; Maurizio Serati; Antonio Raffone; Stefano Salvatore; Marco Torella
Journal:  Medicina (Kaunas)       Date:  2022-07-23       Impact factor: 2.948

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.